Edwin Choy

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Biosimilar safety considerations in clinical practice
    Edwin Choy
    Director of Sarcoma Research, Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA Electronic address
    Semin Oncol 41:S3-14. 2014
  2. pmc High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
    Edwin Choy
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 118:2905-14. 2012
  3. pmc Characterization and analysis of human chordoma cell lines
    Cao Yang
    Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1257-64. 2010
  4. pmc Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study
    Nicole J Look Hong
    Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Eur J Cancer 49:875-83. 2013
  5. pmc The kinase Mirk is a potential therapeutic target in osteosarcoma
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Carcinogenesis 31:552-8. 2010
  6. doi request reprint Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 67:439-46. 2011
  7. pmc Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
  8. pmc Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 5:e10764. 2010
  9. doi request reprint Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas
    John T Mullen
    Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Cancer 118:3758-65. 2012
  10. doi request reprint ROCK1 as a potential therapeutic target in osteosarcoma
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 29:1259-66. 2011

Collaborators

Detail Information

Publications42

  1. doi request reprint Biosimilar safety considerations in clinical practice
    Edwin Choy
    Director of Sarcoma Research, Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA Electronic address
    Semin Oncol 41:S3-14. 2014
    ..Pertinent issues about safety from countries or regions where biosimilars are currently in use also will be reviewed. ..
  2. pmc High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
    Edwin Choy
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 118:2905-14. 2012
    ..The identification of new genes that are mutated in osteosarcomas is critical to developing a better understanding of the molecular pathogenesis of this disease and discovering new targets for therapeutic development...
  3. pmc Characterization and analysis of human chordoma cell lines
    Cao Yang
    Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1257-64. 2010
    ..An experimental study to investigate the characterization of 3 chordoma cell lines...
  4. pmc Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study
    Nicole J Look Hong
    Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Eur J Cancer 49:875-83. 2013
    ..The goal of this study is to assess outcomes in a recent cohort of patients treated on this regimen...
  5. pmc The kinase Mirk is a potential therapeutic target in osteosarcoma
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Carcinogenesis 31:552-8. 2010
    ..This highlights Mirk's potential to serve as a promising target for molecular therapy in the treatment of osteosarcoma...
  6. doi request reprint Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 67:439-46. 2011
    ..To better understand the mechanisms of cytotoxicity and cell death induced by HDACI PCI-24781 in bone sarcoma cells...
  7. pmc Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
    ....
  8. pmc Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 5:e10764. 2010
    ..However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy...
  9. doi request reprint Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas
    John T Mullen
    Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Cancer 118:3758-65. 2012
    ..We report the long-term follow-up data on 48 patients treated with this regimen compared to an historical matched-control patient population...
  10. doi request reprint ROCK1 as a potential therapeutic target in osteosarcoma
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 29:1259-66. 2011
    ..These findings suggest that knockdown of ROCK1 inhibits proliferation and induces apoptosis in osteosarcoma cell lines. ROCK1 may be a promising therapeutic target for the treatment of osteosarcoma patients...
  11. pmc MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 10:1337-45. 2011
    ..Restoring miR-199a-3p's function may provide therapeutic benefits in osteosarcoma...
  12. doi request reprint Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo
    Xianzhe Liu
    Department of Orthopaedic Surgery, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Anticancer Drugs 22:444-53. 2011
    ..Finally, in mouse osteosarcoma xenografts, BI 2536-treated mice had significantly smaller tumors compared with the control mice. These findings offer evidence of the potential role for targeting PLK1 in osteosarcoma therapy...
  13. doi request reprint Targeting hedgehog-GLI-2 pathway in osteosarcoma
    Wen Yang
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 31:502-9. 2013
    ..These findings suggest GLI-2 is required for osteosarcoma cell proliferation and survival. GLI-2 may be exploited as a therapeutic target for the treatment of osteosarcoma patients...
  14. doi request reprint Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Med Chem 55:3113-21. 2012
    ..In conclusion, 11 and derivatives of this compound may hold therapeutic value in the treatment of MDR-dependent cancers...
  15. pmc Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Jackson Building, Boston, Massachusetts 02114, USA
    Mol Cancer Ther 8:2122-30. 2009
    ..Our data suggest that inhibition of IGF-IR with PPP offers a novel and selective therapeutic strategy for ostosarcoma, and at the same time, PPP is effective at reversing the drug-resistant phenotype in osteosarcoma cell lines...
  16. doi request reprint Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Orthop Res 28:746-52. 2010
    ..Our results demonstrate that some miRNAs are differentially expressed in chordoma and, in particular, miRNA-1 may have a functional effect on chordoma tumor pathogenesis...
  17. doi request reprint Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis
    Keinosuke Ryu
    Department of Orthopedic Surgery, Massachusetts General Hospital, Center for Sarcoma and Connective Tissue Oncology, 55 Fruit St Jackson 1115, Boston, Massachusetts 02114, USA
    J Orthop Res 28:971-8. 2010
    ..Our results suggest that Stat3 may be a prognostic indicator and potential therapeutic target for osteosarcoma. Blocking the pathway of Stat3 may lead to develop new therapeutic strategies against osteosarcoma...
  18. doi request reprint Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking
    Michiro Susa
    Department of Orthopaedic Surgery, and SarcomaBiology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 9:3342-50. 2010
    ..In conclusion, our results suggest that osteosarcoma cell proliferation and survival are dependent on GAK. These findings may lead to the development of new therapeutic options for osteosarcoma...
  19. doi request reprint Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Lett 293:220-9. 2010
    ..The development of more potent inhibitors that target PLK1 may open doors to a new range of anti-cancer strategies in osteosarcoma...
  20. doi request reprint Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series
    John T Mullen
    Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA
    Ann Surg Oncol 19:4028-35. 2012
    ..Desmoid tumors are rare and exhibit a highly unpredictable natural history. We sought to analyze prognostic factors associated with recurrence in a large single-institution study of patients with desmoid tumors...
  21. doi request reprint Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology and Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 18:4580-8. 2012
    ..Identification of new targeted therapies is critical to improving the survival rate of patients with osteosarcoma. The goal of this study is to identify kinase based potential therapeutic target in osteosarcomas...
  22. doi request reprint Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay
    Michiro Susa
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Biomol Screen 15:287-96. 2010
    ..The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients...
  23. pmc NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7415. 2009
    ..To date, none of these attempts have yielded a tolerable and effective therapy to reverse MDR; thus, identification of new agents would be useful both clinically and scientifically...
  24. doi request reprint A novel target for treatment of chordoma: signal transducers and activators of transcription 3
    Cao Yang
    Department of Orthopaedic Surgery, Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mol Cancer Ther 8:2597-605. 2009
    ..In conclusion, the Stat3 pathway is constitutively activated in chordomas and the level of expression may serve as a predictor for prognosis. Blockade of the Stat3 pathway represents a potential strategy for future treatment...
  25. doi request reprint Establishment and characterization of a novel chordoma cell line: CH22
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Orthop Res 30:1666-73. 2012
    ....
  26. pmc Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
    Sam S Yoon
    Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 81:1081-90. 2011
    ..We sought to examine the safety and efficacy of bevacizumab (BV) and RT in soft tissue sarcomas and explore biomarkers to help determine the treatment response...
  27. doi request reprint Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St Jackson 1106, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:1121-9. 2009
    ..The present study was performed to elucidate the relationship between the expression of ABCB1/MDR1 and ABCC1/MRP1 with resistance to either ET-743 or PM00104...
  28. doi request reprint Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer
    Yuqi Guo
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 16:5759-69. 2010
    ..We then looked for enhancing paclitaxel sensitivity in multidrug-resistant ovarian cancer cell lines...
  29. doi request reprint Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma
    Cao Yang
    Department of Orthopaedic Surgery, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1668-75. 2010
    ..An experimental study to investigate the activation of Src/Stat3 pathways in chordomas and blockage of this pathway as a potential strategy for chordoma treatment...
  30. pmc Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas
    Sam S Yoon
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 17:1515-29. 2010
    ..We sought to reduce local recurrence for retroperitoneal sarcomas by using a coordinated strategy of advanced radiation techniques and aggressive en-bloc surgical resection...
  31. pmc Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma
    I Frank Ciernik
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Cancer 117:4522-30. 2011
    ..A study was undertaken to assess clinical outcome and the role of proton therapy for local control of osteosarcoma (OSA)...
  32. doi request reprint Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
    Shang Guo
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America Shanghai Sixth People s Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
    PLoS ONE 9:e93996. 2014
    ..Targeting the PI3K/AKT/pathway with small molecule inhibitors in combination with chemotherapy could be exploited as a novel strategy in the treatment of liposarcoma. ..
  33. pmc Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma
    Linlin Zhang
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China
    PLoS ONE 8:e75851. 2013
    ..By Kaplan-Meier analysis, brachyury expression failed to produce any significant relationship with the overall survival rate. In conclusion, brachyury expression is not a prognostic indicator in chordoma. ..
  34. pmc Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute D1212, 450 Brookline Ave, Boston, MA, USA
    J Clin Oncol 30:2401-7. 2012
    ....
  35. doi request reprint Role of epigenetic modulation for the treatment of sarcoma
    Gregory M Cote
    32 Fruit Street, Yawkey 7A, Boston, MA, 02114, USA
    Curr Treat Options Oncol 14:454-64. 2013
    ..We anticipate in the future that diagnostic platforms will be developed to help clinicians determine if an epigenetic therapy could be effective for an individual patient with sarcoma...
  36. ncbi request reprint Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma
    Joseph Schwab
    Department of Orthopedic Surgery, Section of Orthopedic Oncology, Sarcoma Research Laboratory, Massachusetts General Hospital, Boston, MA 02114, U S A
    Anticancer Res 29:1867-71. 2009
    ..PI-103 is a inhibitor of PI3K/AKT and mTOR activation. This study aims to determine whether the PI3K/mTOR pathway was active in chordomas and whether their inhibition could lead to decreased proliferation and increased apoptosis...
  37. doi request reprint Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, 02114
    J Orthop Res 32:695-701. 2014
    ..2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 32:695-701, 2014. ..
  38. doi request reprint Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
    Andrew J Wagner
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5894-902. 2012
    ..This study assessed the activity of tivantinib (ARQ 197), a selective MET inhibitor, in patients with MiT-associated tumors...
  39. pmc ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e6967. 2009
    ..ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood...
  40. doi request reprint Update in treatment and targets in Ewing sarcoma
    Gregory M Cote
    Division of Hematology Oncology, Yawkey Center for Outpatient Care, Massachusetts General Hospital, Harvard Medical School, 32 Fruit Street, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 27:1007-19. 2013
    ..The development of improved preclinical Ewing sarcoma models and advanced molecular techniques will build on knowledge of EWS/FLI1 function, EWS/FLI1 transcription targets, and the other critical driver events in these tumors. ..
  41. doi request reprint Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States Department of Radiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02215, United States Ludwig Center and Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States Electronic address
    Eur J Cancer 50:981-6. 2014
    ..To compare performance of various tumour response criteria (TRCs) in assessment of regorafenib activity in patients with advanced gastrointestinal stromal tumour (GIST) with prior failure of imatinib and sunitinib...
  42. doi request reprint Role of sentinel lymph node biopsy in the staging of synovial, epithelioid, and clear cell sarcomas
    Ugwuji N Maduekwe
    Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
    Ann Surg Oncol 16:1356-63. 2009
    ..The utility of sentinel lymph node biopsy (SLNB) for patients with these sarcoma subtypes is unknown...